drugset / Trial / NCT04626583

Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT04626583 ↗

Non-randomizedSequentialOpen-labelTreatment

Summary

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use digital conjunctival and corneal photography and corneal Scheimpflug Imaging, densitometry, and pachymetry for assessment of safety and corneal wound healing.

Timeline

Start
2021-03-05
Primary completion
2023-04-21
Completion
2023-04-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allogeneic Mesenchymal Stromal Cells Cell therapy 1e+06 cells Other
Comparator Allogeneic Mesenchymal Stromal Cells Cell therapy 3e+06 cells Other
Comparator Allogeneic Mesenchymal Stromal Cells Cell therapy 6e+06 cells Other

Indications